Polaryx Therapeutics names Will Charlton chief medical officer
Polaryx Therapeutics appointed Will Charlton, M.D., M.A.S. as chief medical officer to lead clinical execution for PLX-200 and the SOTERIA Phase 2 trial.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.